CA - MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward

2024-07-18 14:19:35 ET

Summary

• MoonLake Immunotherapeutics launched VELA-1 and VELA-2 as two studies using sonelokimab for the treatment of patients with Hidradenitis Suppurativa; Topline 16-week primary endpoint expected end of 2026.
• The global hidradenitis suppurativa market is expected to reach $1 billion by 2029.
• The initiation of the IZAR program, using sonelokimab for patients with Psoriatic Arthritis, is expected to launch in Q4 of 2024; Primary endpoint data is expected at the end of 2026.
• There is potential to establish a competitive advantage by using Nanobody technology, which incorporates smaller molecules along with drugs developed to target both cytokines IL-17A and IL-17F.

The last time I wrote about MoonLake Immunotherapeutics ( MLTX ) it was in a Seeking Alpha article entitled " MoonLake: Further Gains Possible With End Of 2023 Data Releases. " In the article, I mainly went over the great feat it achieved in using a very challenging to reach primary endpoint of Hidradenitis Suppurativa Clinical Response [HiSCR]75 in the phase 2 MIRA trial. This established a considerable milestone in that sonelokimab was the first drug to achieve this endpoint for this patient population. Having said that, phase 3 studies for this program have been initiated already. This is with the launching of two late-stage studies known as VELA-1 and VELA-2....

For further details see: